David B. Agus () is an American physician and author who serves as a professor of medicine and engineering at the University of Southern California Keck School of Medicine and Viterbi School of Engineering and the Founding Director and CEO of the Lawrence J. Ellison Institute for Transformative Medicine. He is also the cofounder of several personalized medicine companies and a contributor to CBS News on health topics. Agus’s field of expertise is advanced cancer. He has developed new cancer treatments with the aid of private foundations, as well as national agencies including the National Cancer Institute. Agus has also served as chair of the Global Agenda Council on Genetics for the World Economic Forum. He is also the author of three New York Times best selling books. Early life and education Agus graduated cum laude in molecular biology from Princeton University in 1987 and received his medical degree from the University of Pennsylvania Perelman School of Medicine in 1991. He completed his residency training at Johns Hopkins Hospital and completed his oncology fellowship training at Memorial Sloan-Kettering Cancer Center in New York. He spent two years at the National Institutes of Health as a Howard Hughes Medical Institute-NIH Research Scholar. Career Agus has had a long and varied career. At the Lawrence J. Ellison Institute for Transformative Medicine, he leads a team researching prevention and treatments for cancer. He also maintains an oncology practice to apply his team’s research discoveries to the patients under his care. At the Memorial Sloan-Kettering Cancer Center in New York, he was an attending physician in the Department of Medical Oncology and head of the Laboratory of Tumor Biology. He was also Assistant Professor of Medicine at Cornell University Medical Center. As director of the Spielberg Family Center for Applied Proteomics at Cedars-Sinai Medical Center in Los Angeles, he led a multidisciplinary team of researchers dedicated to the development and use of proteomic technologies to guide doctors in making health-care decisions tailored to individual needs. The center grew out of earlier clinical projects at Cedars-Sinai, where Agus served as an attending physician in oncology, which observed striking differences between the aggressiveness of prostate cancer in certain patients and their ability to respond to treatment. Agus also formerly served as Director of the Louis Warschaw Prostate Cancer Center, and as an attending physician in the Department of Medicine, Division of Medical Oncology at Cedars-Sinai Medical